sábado, 14 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 11, 2026

UPS navigates Amazon draw down in hard pivot to premium services

View original at finance.yahoo.com
“Domestic revenue is projected to increase by low-single digits from last year, with an operating margin of about 8%.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Primary cause of lower volumes was deliberate decision to shed 50% of Amazon volume because it didn't make money

    60% confidence
  • UPS cost-reduction program is positioning company for profitable growth, creating more agile and profitable network to grow with right type of volume

    60% confidence
  • FedEx is prioritizing high-value B2B segments and premium e-commerce over last-mile delivery

    60% confidence
  • Analysts are giving UPS solid marks in executing largest network consolidation in its history without noticeable impact on service levels

    60% confidence
  • UPS strategic focus shifting to less e-commerce, more small-and-medium business, more B2B, more healthcare

    60% confidence
  • UPS expects soft revenue environment and operational adjustment costs to weigh on profits in first half of year, with improvement in second half as efficiency measures flow to bottom line

    60% confidence

Data points we hold from this source

United Parcel Service · amazon throughput reduction2000000 pieces_per_day
United Parcel Service · revenue reduction amazon5 USD
United Parcel Service · amazon volume reduction50 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
UPS navigates Amazon draw down in hard pivot to premium services — Source | Via News | pt.VIA.NEWS